A Phase 1b Dose De-escalation Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of MYC Oncogene Overexpression
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Dinaciclib (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 16 Apr 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 16 Apr 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 10 Jun 2017 Biomarkers information updated